Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD17002 in eosinophilic asthma
NCT07250594Phase 2Not yet recruiting
- Sponsor
- Advagene Biopharma Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AD-17002 in eosinophilic asthma (EA) (3 arms), sponsored by Advagene Biopharma Co., Ltd. Primary endpoint: Safety and tolerability endpoint. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
AD-17002
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT07250594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250594.